Cargando…
Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective
The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of prod...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136377/ https://www.ncbi.nlm.nih.gov/pubmed/32144742 http://dx.doi.org/10.1007/s13300-020-00777-2 |
_version_ | 1783518234963607552 |
---|---|
author | Haluzík, Martin Flekač, Milan Lengyel, Csaba Taybani, Zoltán Guja, Cristian Mihai, Bogdan-Mircea Cerghizan, Anca Martinka, Emil Kovacs, Gabor Kempler, Péter |
author_facet | Haluzík, Martin Flekač, Milan Lengyel, Csaba Taybani, Zoltán Guja, Cristian Mihai, Bogdan-Mircea Cerghizan, Anca Martinka, Emil Kovacs, Gabor Kempler, Péter |
author_sort | Haluzík, Martin |
collection | PubMed |
description | The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of product characteristics. In April 2019, a scientific meeting was held with the participation of nine experts from four Central and Eastern European countries to provide expert consensus on the optimal daily use of the insulin glargine and lixisenatide FRC (iGlarLixi). Topics included the positioning and initiation of iGlarLixi and the management of treatment. This paper summarizes the outcomes of the meeting. |
format | Online Article Text |
id | pubmed-7136377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-71363772020-04-09 Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective Haluzík, Martin Flekač, Milan Lengyel, Csaba Taybani, Zoltán Guja, Cristian Mihai, Bogdan-Mircea Cerghizan, Anca Martinka, Emil Kovacs, Gabor Kempler, Péter Diabetes Ther Practical Approach The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of product characteristics. In April 2019, a scientific meeting was held with the participation of nine experts from four Central and Eastern European countries to provide expert consensus on the optimal daily use of the insulin glargine and lixisenatide FRC (iGlarLixi). Topics included the positioning and initiation of iGlarLixi and the management of treatment. This paper summarizes the outcomes of the meeting. Springer Healthcare 2020-03-06 2020-04 /pmc/articles/PMC7136377/ /pubmed/32144742 http://dx.doi.org/10.1007/s13300-020-00777-2 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Practical Approach Haluzík, Martin Flekač, Milan Lengyel, Csaba Taybani, Zoltán Guja, Cristian Mihai, Bogdan-Mircea Cerghizan, Anca Martinka, Emil Kovacs, Gabor Kempler, Péter Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective |
title | Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective |
title_full | Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective |
title_fullStr | Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective |
title_full_unstemmed | Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective |
title_short | Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective |
title_sort | expert opinion on the therapeutic use of the fixed-ratio combination of insulin glargine 100 u/ml and lixisenatide: a central/eastern european perspective |
topic | Practical Approach |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136377/ https://www.ncbi.nlm.nih.gov/pubmed/32144742 http://dx.doi.org/10.1007/s13300-020-00777-2 |
work_keys_str_mv | AT haluzikmartin expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective AT flekacmilan expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective AT lengyelcsaba expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective AT taybanizoltan expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective AT gujacristian expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective AT mihaibogdanmircea expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective AT cerghizananca expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective AT martinkaemil expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective AT kovacsgabor expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective AT kemplerpeter expertopiniononthetherapeuticuseofthefixedratiocombinationofinsulinglargine100umlandlixisenatideacentraleasterneuropeanperspective |